What does XomeXBio do?

XomeXBio is a research organisation in Charleroi. Private Limited, started on 17 May 2023, 1 establishment.

What is the address of XomeXBio?

The registered office of XomeXBio is located at Rue Clément Ader 10, 6041 Charleroi.

Is XomeXBio still active?

Yes. According to the CBE (29 October 2026) XomeXBio is active, legal situation “Normale toestand”, started on 17 May 2023.

Is XomeXBio registered on Peppol?

Yes, XomeXBio is registered on the Peppol network with ID 0208:0801880687.

What is the enterprise number of XomeXBio?

The enterprise number of XomeXBio is BE0801880687.

When was XomeXBio founded?

XomeXBio was founded on 17 May 2023.

Who are the directors of XomeXBio?

According to the 2025 annual accounts, the directors of XomeXBio are: Hui Yang, JPP CONSULTING, TONGLET CONSULT, Chen Sihui.

Is XomeXBio a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 May 2023; 3 annual accounts filed, latest fiscal year 2025; 4 directors known from the annual account.

How much profit did XomeXBio make in 2025?

XomeXBio recorded a loss after taxes of € 528,922 in financial year 2025.

What is the revenue of XomeXBio?

As a small company, XomeXBio is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 103,430.

How much does an employee at XomeXBio earn?

The average wage cost per full-time employee at XomeXBio was € 87,700 in 2025: staff costs of € 350,819 for 4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does XomeXBio have?

According to the 2025 annual accounts, XomeXBio has 4 full-time equivalents (FTE).

XomeXBio (Private Limited) - Charleroi - BE0801880687

Dossier XomeXBio, printed on 29 October 2026 from databakkes.be/en/0801880687/xomexbio. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Busy address KBO

31 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

XomeXBio from Charleroi, company number BE0801880687, closed financial year 2025 with a result of € -528,922 after tax. For that financial year XomeXBio recorded a gross margin of € 103,430 and equity of € 1.1 million. Compared with financial year 2024, the result moved from € -595,305 to € -528,922. The company made a loss. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 15, 2026.

What it is worth Growing

€ 1.1 million

▲ € 988,362 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -528,922

▲ 11 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 81,980

▲ 193% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -129,499.

People and assets in 2025

Full-time equivalents

▼ 0.8 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 350,819

▼ 12% vs 2024

€ 87,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 2,042

▼ 43% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 198,667

▼ 39% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 23,876

▼ 82% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 9,707 Gross margin 2023: € 9,707 First fiscal year in the series	€ -48,756 Gross margin 2024: € -48,756 ▼ € 58,463 vs 2023 (€ 9,707) Unfavourable step	€ 103,430 Gross margin 2025: € 103,430 ▲ € 152,186 vs 2024 (€ -48,756) Favourable step	▲ € 152,186
Profit after taxes	€ -6,337 Profit after taxes 2023: € -6,337 First fiscal year in the series	€ -595,305 Profit after taxes 2024: € -595,305 ▼ € 588,968 vs 2023 (€ -6,337) Unfavourable step	€ -528,922 Profit after taxes 2025: € -528,922 ▲ € 66,383 vs 2024 (€ -595,305) Favourable step	▲ € 66,383
Equity	€ 93,663 Equity 2023: € 93,663 First fiscal year in the series	€ 67,716 Equity 2024: € 67,716 ▼ 28% vs 2023 (€ 93,663) Unfavourable step	€ 1,056,078 Equity 2025: € 1,056,078 ▲ € 988,362 vs 2024 (€ 67,716) Favourable step	▲ € 988,362
Total debts	€ 1,759,343 Total debts 2023: € 1,759,343 First fiscal year in the series	€ 1,454,951 Total debts 2024: € 1,454,951 ▼ 17% vs 2023 (€ 1,759,343) Favourable step	€ 2,443,479 Total debts 2025: € 2,443,479 ▲ 68% vs 2024 (€ 1,454,951) Unfavourable step	▲ 68%
Cash	€ 1,845,085 Cash 2023: € 1,845,085 First fiscal year in the series	€ 27,984 Cash 2024: € 27,984 ▼ 98% vs 2023 (€ 1,845,085) Unfavourable step	€ 81,980 Cash 2025: € 81,980 ▲ 193% vs 2024 (€ 27,984) Favourable step	▲ 193%
Retained profit	€ -6,337 Retained profit 2023: € -6,337 First fiscal year in the series	€ -601,643 Retained profit 2024: € -601,643 ▼ € 595,305 vs 2023 (€ -6,337) Unfavourable step	€ -129,499 Retained profit 2025: € -129,499 ▲ € 472,144 vs 2024 (€ -601,643) Favourable step	▲ € 472,144
Bank debt	€ 787 Bank debt 2023: € 787 First fiscal year in the series	€ 0 Bank debt 2024: € 0 ▼ 100% vs 2023 (€ 787) Favourable step	€ 0 Bank debt 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 1,853,005 Balance sheet total 2023: € 1,853,005 First fiscal year in the series	€ 1,522,667 Balance sheet total 2024: € 1,522,667 ▼ 18% vs 2023 (€ 1,853,005) Unchanged	€ 3,499,557 Balance sheet total 2025: € 3,499,557 ▲ 130% vs 2024 (€ 1,522,667) Unchanged	▲ 130%
Employees (FTE)	0.1 Employees (FTE) 2023: 0.1 First fiscal year in the series	4.8 Employees (FTE) 2024: 4.8 ▲ 4.7 vs 2023 (0.1) Unchanged	4 Employees (FTE) 2025: 4 ▼ 0.8 vs 2024 (4.8) Unchanged	▼ 0.8

Key figures of XomeXBio, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to XomeXBio?

What happened at XomeXBio in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 15, 2026 New annual accounts for financial year 2025: loss of € 528,922. Source: NBB ↗
2024 Hui Yang became a director. NBB
2024 TONGLET CONSULT became a director. NBB
2024 Chen Sihui became a director. NBB
May 17, 2023 New establishment in Charleroi. KBO
2023 JPP CONSULTING became a director. NBB
May 17, 2023 Start of the company according to the CBE. KBO

In short

From € 6,337 loss in 2023 to € 528,922 loss in 2025.

Paid € 799 in corporate taxes since 2023.

On average € 25,900 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Hui Yang JPP CONSULTING TONGLET CONSULT Chen Sihui

CURAVAC EUROPE

ConvEyXo

PDC line Pharma

XomeXBio

Behind XomeXBio are Hui Yang, JPP CONSULTING, TONGLET CONSULT and Chen Sihui. JPP CONSULTING is also behind CURAVAC EUROPE, PDC line Pharma, ConvEyXo and Exo-Harvest. TONGLET CONSULT is also behind ConvEyXo and Exo-Harvest.

Directors

According to the 2025 annual accounts

Hui Yang

Director

since 2024

JPP CONSULTING

Director · represented by Jean PRIEELS

Also active at: CURAVAC EUROPE, PDC line Pharma, ConvEyXo, Exo-Harvest

since 2023

TONGLET CONSULT

Director · represented by Frédéric TONGLET

Also active at: ConvEyXo, Exo-Harvest

since 2024

Chen Sihui

Director

since 2024

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Clément Ader 10

6041 Charleroi

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 31 companies are registered at this address.

All companies at this address →

Brussels South Charleroi BioPark Dev

€ 80,186 gross margin · 2025

ImmunXperts

€ 393,338 gross margin · 2024

LYS MEDICAL

€ -309,203 gross margin · 2025

SPECTRALYS BIOTECH

€ 143,689 gross margin · 2025

ProtonW.be

€ -7,643 gross margin · 2025

+26 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0801.880.687
VAT number: BE 0801.880.687
Registered office: Rue Clément Ader 10, 6041 Charleroi
Names & denominations: XomeXBio
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 17 May 2023
Peppol: Active · Active since 5 Jun 2023
Activities · NACE: Speur- en ontwikkelingswerk op biotechnologisch gebied

View on CBE Public ↗ Annual accounts (NBB) ↗

XomeXBio

Warning lights

Financials

What happened to XomeXBio?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions